H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
14%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Cardiotoxicity following different doses and schedules of 5-fluorouracil administrationfor malignancy -- a survey of 427 patients.

Maria Vadiaka, Michalis Efremidis, Andreas Zinelis, Christos Kosmas, Nicolas Tsavaris, Dimitris Beldecos, Dimitris Sakelariou, Christos Koufos, George Stamatelos

Med Sci Monit 2002; 8(6): PI51-57

ID: 420798

Available online:

Published: 2002-06-18


BACKGROUND: Although cardiotoxicity associated with 5-Fluorouracil (5-FU)administration is infrequent, there are case reports of acute coronary syndromes. We report on patientsundergoing 5-FU chemotherapy who developed cardiac symptoms during its administration.MATERIAL/METHODS:In patients receiving 5-FU who experienced cardiac-related symptoms, ECG and serum cardiac enzyme determinationwere performed. If cardiotoxicity was detected, 5-FU infusion was interrupted, and the patients receivedsublingual nitrates and cardiac monitoring, while patients with more than 2-fold elevated enzyme levelswere monitored in a coronary care unit for at least 72 hours. In cases of acute myocardial infarction,5-FU was terminated.RESULTS: Of 427 patients entering the study, 17 (4%) developed clinical symptomsand ECG abnormalities indicating 5-FU cardiotoxicity. Patients with continuous infusion (c.i.) of 5-FUhad a higher incidence of cardiotoxicity (12/197, 6%) than the remaining (5/235, 2.1%) (p=0.067), butmore toxicity was encountered in patients with c.i. of 5-FU+LV for 24 hours for 5 days than in patientswith the same regimen of 5-FU without LV (p

Keywords: Antimetabolites, Antineoplastic, Dose-Response Relationship, Drug, Drug Administration Schedule, Electrocardiography, Fluorouracil, Heart, Neoplasms



Back